Lack of Accuracy for the Proposed ‘Dubois Criteria’ in Alzheimer’s Disease: A Validation Study from the Swedish Brain Power Initiative

Background/Aims: Our purpose was to investigate whether the new research criteria for Alzheimer’s disease proposed in 2007 by Dubois et al. are valid in a naturalistic memory clinic sample. Method: Retrospective diagnostic analyses were carried out to compare the traditional diagnostic criteria for dementia with the new criteria suggested by Dubois et al. No patient had gone through all procedures postulated as additional features in the proposed new Dubois criteria. Material: Two independent experienced geriatricians re-examined 150 complete patients’ records. The study physicians were blinded to any of the results of the core and additional features suggested by Dubois et al. to avoid circular diagnostic bias. Results:Among our 96 patients with a clinical diagnosis of subjective cognitive impairment and/or mild cognitive impairment, 2 of the patients with subjective cognitive impairment and 5 patients with mild cognitive impairment would classify as pre-dementia Alzheimer’s disease according to the Dubois criteria. In our 23 Alzheimer patients diagnosed clinically, only 12 of the cases fulfilled the criteria for Alzheimer’s disease suggested by Dubois et al. Interpretation: The proposed new criteria for Alzheimer’s disease are valid in 55% of our patients clinically diagnosed as having full-blown Alzheimer dementia. Additionally, 7.3% ‘true’ Alzheimer cases will be identified in a group of 96 clinically non-demented patients. Our results show that there is a large heterogeneity in a clinical naturalistic sample of patients with an Alzheimer phenotype. Conclusion: There is a need to further validate the currently existing biomarkers in large unselected samples and avoid the pitfall of workup bias and circular diagnostic processes. Additionally, valid age-specific cut-off values for the diagnostic markers in question have to be defined.

[1]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[3]  P. Scheltens,et al.  Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer’s Disease – Data from the ICTUS Study , 2008, Dementia and Geriatric Cognitive Disorders.

[4]  P. Scheltens,et al.  Revised research diagnostic criteria for Alzheimer's disease , 2008, The Lancet Neurology.

[5]  H. Soininen,et al.  Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer’s Disease , 2008, Neuroepidemiology.

[6]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[7]  J. Jolles,et al.  Ten-year risk of dementia in subjects with mild cognitive impairment , 2006, Neurology.

[8]  Karalyn Patterson,et al.  Evolution of Cognitive Deficits and Conversion to Dementia in Patients with Mild Cognitive Impairment: A Very-Long-Term Follow-Up Study , 2006, Dementia and Geriatric Cognitive Disorders.

[9]  O. Almkvist,et al.  Identifying Patients at High and Low Risk of Cognitive Decline Using Rey Auditory Verbal Learning Test among Middle-Aged Memory Clinic Outpatients , 2006, Dementia and Geriatric Cognitive Disorders.

[10]  P. Scheltens,et al.  Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer’s Disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[12]  K. Blennow,et al.  CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival , 2006, Dementia and Geriatric Cognitive Disorders.

[13]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[14]  L. Wahlund,et al.  Mild cognitive impairment: experience from a memory clinic , 2003, Acta neurologica Scandinavica. Supplementum.

[15]  Piotr J. Slomka,et al.  Automated segmentation and registration technique for HMPAO-SPECT imaging of Alzheimer's patients , 2000, Medical Imaging: Image Processing.

[16]  A. Hofman,et al.  Rates and risk factors for dementia and Alzheimer’s disease , 1999, Neurology.

[17]  Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[18]  Amos D. Korczyn,et al.  Vascular dementia , 1993, Journal of the Neurological Sciences.

[19]  David Goldblatt,et al.  Slowly progressive aphasia , 1993, Neurology.

[20]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[21]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .